Elevated IL‑6/IL‑1Ra ratio as a prognostic biomarker of poor chemotherapy efficacy in Chinese patients with metastatic NSCLC, validated in a Caucasian patient cohort

Liu,Fang; Sansas,Benoît; Préville,Xavier; Gineste,Romain; Wang,Jialei; Yu,Hui; Meng,Xia; Micol,Romain; Barraud,Luc

doi:10.3892/mco.2018.1788

Elevated IL‑6/IL‑1Ra ratio as a prognostic biomarker of poor chemotherapy efficacy in Chinese patients with metastatic NSCLC, validated in a Caucasian patient cohort

Authors:
- Fang Liu
- Benoît Sansas
- Xavier Préville
- Romain Gineste
- Jialei Wang
- Hui Yu
- Xia Meng
- Romain Micol
- Luc Barraud
View Affiliations

Affiliations: Transgene Biopharmaceutical Technology Co. Ltd., Shanghai 201315, P.R. China, Research and Innovation Department, Transgene S.A., 67405 Illkirch Graffenstaden, France, Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 201315, P.R. China
Published online on: December 11, 2018 https://doi.org/10.3892/mco.2018.1788
Pages: 309-317

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The treatment options for advanced (stage IV) non‑small cell lung cancer (NSCLC) at diagnosis remain disappointing. The development of immunotherapeutic drugs may represent a promising alternative approach to the treatment of late‑stage cancer at diagnosis. These current paradigms in cancer treatment highlight the need for new biomarkers related to the immune status of the patients and/or the tumor microenvironment, for immune as well as chemotherapeutic treatment options. The aim of the present study was to analyze soluble immune factors in patients with lung cancer treated with chemotherapy to identify prognostic biomarkers. For this purpose, the data obtained from two cohorts of patients from different clinical trials were analyzed: A Chinese patient cohort to identify potential prognostic biomarkers, and a validation cohort comprising patients with a similar clinical stage from a clinical trial in Europe. Analyses of soluble markers for inflammation and immune status were performed by standard assays and multiplex Luminex assays. Differences in overall survival (OS) and progression‑free survival (PFS) were evaluated with the log‑rank test and robustness was evaluated with the resampling approach. In the Chinese cohort, four prognostic biomarkers of poor response to chemotherapy were identified, which had a significant impact on OS and PFS. It was confirmed in the Caucasian validation cohort that an increased value of the interleukin (IL)-6/IL‑1Ra cytokine ratio at inclusion was correlated with significantly shorter OS and PFS, whereas no other biomarkers were found to be significant. The IL‑6/IL‑1Ra ratio reflects the imbalance between pro‑ and anti‑inflammatory status in the plasma of patients and may be associated with tumor inflammatory status and the therapeutic outcome. The present study highlights the identification of the IL‑6/IL‑1Ra ratio as a biomarker of poor prognosis in terms of response to chemotherapy in two independent clinical studies.

View Figures

View References

1	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
2	Scagliotti G, Hanna N, Fossella F, Sugarman K, Blatter J, Peterson P, Simms L and Shepherd FA: The differential efficacy of pemetrexed according to NSCLC histology: A review of two phase III studies. Oncologist. 14:253–263. 2009. View Article : Google Scholar : PubMed/NCBI
3	Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, et al: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 26:3543–3551. 2008. View Article : Google Scholar : PubMed/NCBI
4	Santabarbara G, Maione P, Rossi A, Palazzolo G and Gridelli C: Novel immunotherapy in the treatment of advanced non-small cell lung cancer. Expert Rev Clin Pharmacol. 9:1571–1581. 2016. View Article : Google Scholar : PubMed/NCBI
5	Daud AI, Wolchok JD, Robert C, Hwu WJ, Weber JS, Ribas A, Hodi FS, Joshua AM, Kefford R, Hersey P, et al: Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma. J Clin Oncol. 34:4102–4109. 2016. View Article : Google Scholar : PubMed/NCBI
6	Bremnes RM, Busund LT, Kilvær TL, Andersen S, Richardsen E, Paulsen EE, Hald S, Khanehkenari MR, Cooper WA, Kao SC and Dønnem T: The role of tumor-infiltrating lymphocytes in development, progression, and prognosis of non-small cell lung cancer. J Thorac Oncol. 11:789–800. 2016. View Article : Google Scholar : PubMed/NCBI
7	Teng F, Meng X, Wang X, Yuan J, Liu S, Mu D, Zhu H, Kong L and Yu J: Expressions of CD8+TILs, PD-L1 and Foxp3+TILs in stage I NSCLC guiding adjuvant chemotherapy decisions. Oncotarget. 7:64318–64329. 2016. View Article : Google Scholar : PubMed/NCBI
8	McLemore LE, Janakiram M, Albanese J, Shapiro N, Lo Y, Zang X and Fineberg S: An immunoscore using PD-L1, CD68, and Tumor-infiltrating Lymphocytes (TILs) to predict response to neoadjuvant chemotherapy in invasive breast cancer. Appl Immunohistochem Mol Morphol. 26:611–619. 2018.PubMed/NCBI
9	Zhang P, Ma Y, Lv C, Huang M, Li M, Dong B, Liu X, An G, Zhang W, Zhang J, et al: Up-regulation of programmed cell death ligand 1 promotes resistance response in non-small cell lung cancer patients with neo-adjuvant chemotherapy. Cancer Sci. 107:1563–1571. 2016. View Article : Google Scholar : PubMed/NCBI
10	Mesnage SJL, Auguste A, Genestie C, Dunant A, Pain E, Drusch F, Gouy S, Morice P, Bentivegna E, Lhomme C, et al: Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC). Ann Oncol. 28:651–657. 2017.PubMed/NCBI
11	Vacchelli E, Aranda F, Eggermont A, Galon J, Sautès-Fridman C, Cremer I, Zitvogel L, Kroemer G and Galluzzi L: Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology. 3:e278782014. View Article : Google Scholar : PubMed/NCBI
12	Leung EY, Scott HR and McMillan DC: Clinical utility of the pretreatment glasgow prognostic score in patients with advanced inoperable non-small cell lung cancer. J Thorac Oncol. 7:655–662. 2012. View Article : Google Scholar : PubMed/NCBI
13	Proctor MJ, Morrison DS, Talwar D, Balmer SM, O'Reilly DS, Foulis AK, Horgan PG and McMillan DC: An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: A glasgow inflammation outcome study. Br J Cancer. 104:726–734. 2011. View Article : Google Scholar : PubMed/NCBI
14	Kalra J and Baker J: Multiplex immunohistochemistry for mapping the tumor microenvironment. Methods Mol Biol. 1554:237–251. 2017. View Article : Google Scholar : PubMed/NCBI
15	Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, Angell H, Fredriksen T, Lafontaine L, Berger A, et al: Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 39:782–795. 2013. View Article : Google Scholar : PubMed/NCBI
16	Lippitz BE: Cytokine patterns in patients with cancer: A systematic review. Lancet Oncol. 14:e218–e228. 2013. View Article : Google Scholar : PubMed/NCBI
17	Lippitz BE and Harris RA: Cytokine patterns in cancer patients: A review of the correlation between interleukin 6 and prognosis. Oncoimmunology. 5:e10937222016. View Article : Google Scholar : PubMed/NCBI
18	Yu H, Liu F, Sansas B, Kang B, Preville X, Wu X, Chang J, Micol R, Wang J and Meng X: Typing of killer-cell immunoglobulin-like receptors and their cognate human leukocyte antigen class I ligands predicts survival of Chinese Han patients with metastatic non-small-cell lung cancer. Mol Clin Oncol. 6:279–285. 2017. View Article : Google Scholar : PubMed/NCBI
19	Quoix E, Ramlau R, Westeel V, Papai Z, Madroszyk A, Riviere A, Koralewski P, Breton JL, Stoelben E, Braun D, et al: Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: A controlled phase 2B trial. Lancet Oncol. 12:1125–1133. 2011. View Article : Google Scholar : PubMed/NCBI
20	Fluss R, Faraggi D and Reiser B: Estimation of the Youden Index and its associated cutoff point. Biom J. 47:458–472. 2005. View Article : Google Scholar : PubMed/NCBI
21	Naugler WE and Karin M: The wolf in sheep's clothing: The role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med. 14:109–119. 2008. View Article : Google Scholar : PubMed/NCBI
22	Yu H, Lee H, Herrmann A, Buettner R and Jove R: Revisiting STAT3 signalling in cancer: New and unexpected biological functions. Nat Rev Cancer. 14:736–746. 2014. View Article : Google Scholar : PubMed/NCBI
23	Wang YS, Miao LY, Liu L, Cai HR, Ding JJ, Ren SX, Zhou CC and Schmid-Bindert G: Serum cytokine levels in patients with advanced non-small cell lung cancer: Correlation with clinical outcome of erlotinib treatment. Chin Med J (Engl). 126:3931–3935. 2013.PubMed/NCBI
24	Wang Z, Wu P, Wu D, Zhang Z, Hu G, ZhaoS, Lai Y and Huang J: Prognostic and clinicopathological significance of serum interleukin-6 expression in colorectal cancer: A systematic review and meta-analysis. Onco Targets Ther. 8:3793–3801. 2015. View Article : Google Scholar : PubMed/NCBI
25	Lewis AM, Varghese S, Xu H and Alexander HR: Interleukin-1 and cancer progression: The emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment. J Transl Med. 4:482006. View Article : Google Scholar : PubMed/NCBI
26	Mantovani A, Allavena P, Sica A and Balkwill F: Cancer-related inflammation. Nature. 454:436–444. 2008. View Article : Google Scholar : PubMed/NCBI
27	Landskron G, De la Fuente M, Thuwajit P, Thuwajit C and Hermoso MA: Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res. 2014:1491852014. View Article : Google Scholar : PubMed/NCBI